The scientific objective of the Basser Center for BRCA includes the funding of cutting-edge cancer research projects related to BRCA1/2 gene mutations ranging from basic science to clinical and translational research with an emphasis on collaborative projects shared between groups of scientists. To date, the Center has awarded nearly $15 million in internal and external grant funding to scientists at the University of Pennsylvania and throughout the nation, including recent projects at University of Massachusetts, Yale, and University of Virginia. More information on these grants can be found in the Current Grant Awardees section below.
This external grants program, unusual among scientific centers, is made possible by a $5 million donation in 2014 by University of Pennsylvania alumni Mindy and Jon Gray. Their total giving to Penn is $55 million, following a $25 million gift that established the Basser Center in 2012. The Center was created in memory of Mindy Gray’s sister Faith Basser, who died of BRCA-related ovarian cancer at age 44.
Internal Funding (for Penn Investigators)
Request for Applications: The Basser Center has the unique opportunity to catalyze research to change the paradigm of discovery, innovation, and care for issues related to BRCA1 and BRCA2 mutations. Germline mutations in BRCA1 and BRCA2 significantly increase the risk of breast and ovarian cancer and also are associated with prostate cancer and pancreatic cancer. Towards this end, the Basser Center seeks applications that propose innovative approaches to the focus areas listed below:
- Improved understanding of the mechanisms by which BRCA1/2 mutations lead to tumor initiation focusing on issues with potential translational implications. Examples might include tissue specificity and identification of pathways for the development of novel therapeutics.
- Development of projects leading to improvements in cancer screening for BRCA1/2 mutation carriers. Examples might be development of novel imaging or screening approaches, or biomarkers for early detection.
- Improve understanding of mechanisms by which BRCA1/2 mutant cancers develop resistance to PARP inhibitors, platinum salts and other therapies. Projects should increase basic understanding of molecular events that enable resistance to these agents in cells lacking functional BRCA1/2. Ideally, proposal should also involve strategies to overcome clinically validated resistance mechanisms.
- Development of immune approaches for prevention of BRCA1/2 related tumors, which might be informed by the understanding of tumor progression and/or somatic genetics in BRCA1/2 related tumors.
- Strategies to improve the availability and uptake of genetic testing for BRCA1/2 in appropriate individuals.
The internal grants program is now closed to new applications and will reopen in 2019.
For questions related to the external grants program, contact Beth Stearman, Administrative Director for the Basser Center, or call 215.349.8657.
The Basser Center for BRCA at Penn Medicine’s Abramson Cancer Center announces the Basser External Research Grant Program, which focuses on projects that have the potential to advance the care of individuals living with BRCA1 and BRCA2 mutations. Research grant applications in basic science, prevention, early detection, or targeted therapeutics and relevant to the study of BRCA1/2 will be considered. This funding mechanism is not intended for faculty at the University of Pennsylvania. Grants that demonstrate a potential for translation into clinical practice will be prioritized for funding.
- Basser Innovation Award: Three $100,000, one-year, high-risk idea projects will be awarded. Six-month progress updates are required. A three-month notice of termination will be given if lack of progress is demonstrated. Final reports are required.
A mandatory letter of intent (LOI) is due by Monday, December 17, 2018.
THE DEADLINE FOR FULL APPLICATIONS IS 5:00 PM (EST) ON MONDAY, JANUARY 28, 2019.
Review and Notification:
- All applications will be reviewed by an External Review Committee and successful applicants will be announced in April 2019. Funding will have a start date of July 1, 2019.
Detailed information and instructions are available here: https://www.pennmedicine.org/cancer/cancer-research/for-researchers/investigators-only/funding-opportunities
For questions related to the external grants program, contact Cecilia Scavellii, Associate Director for Research Administration at the Abramson Cancer Center, or call 215.349.8387.
Current Grant Awardees
PARPi resistance mutations of PARP-1 in BRCA1/2 mutant cancers
Principal Investigator Ben Black, PhD, is funded to explore the mechanistic underpinnings of how mutations in the PARP-1 enzyme generate resistance to PARP inhibitors (PARPi) as has been observed in the clinic during the treatment of breast and ovarian cancer. Using expertise in studying protein/DNA complexes with hydrogen/deuterium exchange coupled to mass spectrometry (HXMS) and a longstanding and productive collaboration with the world-leading PARP crystallographer (John Pascal, Université de Montréal) and establishing a new collaboration with an expert in PARPi strategies in BRCA1/2 deficient cancers (Chris Lord, ICR, London), the study will now determine the physical basis for PARP-1 PARPi resistance driver mutations. Specifically, the focus will be on mutations that are likely to involve disruption of the PARP-1 allosteric network. This mechanism of resistance is particularly relevant to the many BRCA1/2 deficient breast and ovarian tumors where residual BRCA1 activity allows resistance mutations of PARP-1 where its activity is lowered and/or eliminated.
Core resource for clinical studies of PET imaging of PARP-1 to direct targeted cancer therapy
Principal Investigators Mehran Makvandi, PharmD, and Austin Pantel, MD, are funded to develop a shared resource for clinical studies of PET (positron emission tomography) imaging of PARP-1 (Poly [ADP-ribose] polymerase 1) to direct targeted cancer therapy. This resource provides common services and infrastructure to support ongoing PARP imaging projects in breast, ovarian, pancreatic, and prostate cancer, and will assist with translational research and the data management of clinical trials. This resource will enable multiple research teams to work together to answer fundamental questions to evaluate [18F]FTT as a biomarker to predict and monitor response to chemotherapy and PARPi. This shared resource will provide support for radiotracer production, image analysis, clinical data mining, and data analysis for the existing projects in this space.
Implication of Gleason score for the precision medicine treatment of patients with localized prostate cancer
Kara Maxwell, MD, PhD, is the Principal Investigator on this study funded to investigate alterations in BRCA1/2-related prostate cancer. This study aims to utilize the robust resources of the Penn Medicine Biobank and PennOmics to study the relationship of BRCA1/2 mutations to Gleason score in prostate cancer patients at Penn Medicine. Genomic predictors of response to DNA damaging agents, specifically measures of homologous recombination deficiency, and mutational signatures suggestive of tumor etiology will be analyzed in the prostate tumors of patients with BRCA1/2 mutations. Concurrently, specimens from all Gleason 9-10 prostate cancer patients with BRCA1/2 mutations undergoing radical prostatectomy will be prospectively collected for the development of a tumor organoid bank to study therapy response. The results of this study will further clarify the role of BRCA1/2 in the development of prostate cancer and may directly inform the precision medicine treatment of patients with localized prostate cancer.
DDR-inhibitor combinations for the treatment of BRCA1/2 germline carriers
Principal Investigators Fiona Simpkins, MD, and Eric Brown, PhD, are funded to explore preliminary findings that distinct combinations of PARPi, ATRi and WEE1i differ in treatment effectiveness depending on BRCA status in high-grade serous ovarian cancers (HGSOC). The aims of the study include determining the most effective combination strategies for BRCA1/2 germline carriers using patient-derived xenograph models and identifying both mechanisms of response and resistance with state-of-the-art proteomic and genomic technologies. These studies will determine how best to implement these next-generation treatment combinations in the clinic in a manner that is customized to the genetics of the HGSOC.
TERT DNA vaccination and immune modulation in a BRCA mutant mouse model of pancreatic cancer
Principal investigators Robert H. Vonderheide, MD, DPhil, and David B. Weiner, PhD (The Wistar Institute) are funded to explore the use of a TERT DNA vaccination in combination with immune modulation to prevent tumor development in a BRCA2 deficient pancreatic cancer model. This is a continuation of research that began during a Basser Team Science award, where the Weiner and Vonderheide laboratories collaborated to i) demonstrate synergy between TERT DNA immunization and immune checkpoint blockade in other tumor models, and to ii) develop a transgenic pancreatic ductal adenocarcinoma model lacking BRCA2 expression, termed the KPC-B model. In continuation of this work, this team will examine the impact of TERT DNA immunization either alone,in combination with immune checkpoint inhibitors targeting CTLA4 or PD1, or in combination with CD40 mAb or CD40L plasmid adjuvant using the KPC-B model. Their goal is to utilize these pre-clinical results to design a clinical trial for immunization of high risk BRCA1/2 mutation carriers.
Basser Core Investigators
Angela Bradbury, MD
The REACH study (A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast and Ovarian Cancer Patients) will evaluate the effectiveness of a theoretically and stake-holder informed eHealth delivery alternative to traditional genetic counseling in patients with advanced breast and ovarian cancer. Dr. Bradbury expects this alternative delivery model for genetic testing has the potential to provide equal or improved patient outcomes, while reducing patient and genetic provider time and increasing uptake of testing in patients who can benefit from genetic testing. The study is anticipated to open in Spring 2019 and will recruit over 400 patients with advanced breast and ovary cancer.
Ronny Drapkin, MD, PhD
There are currently no animal models of ovarian cancer that are faithful to the origins of the disease (e.g. the fallopian tubes), recapitulate the genomic complexity of the human condition, and allow for the study the tumor-host (e.g. microenvironment) interactions. In order to create such a model, Dr. Drapkin’s laboratory isolated cells from the fallopian tubes of mice with a normal immune response and used genome-editing to create defects in key oncogenes and tumor suppressor genes that would allow for a tumor to form when implanting the cells back into the abdominal cavity of the mouse. The first of such tumors have been isolated from these mice and they exhibit the characteristic features of human high-grade serous carcinoma. Molecular characterization of the tumors, including genomic and epigenetic profiling, is ongoing. Dr. Drapkin’s team is also beginning the process of addressing how the immune system reacts to these tumors and whether the genetic make-up of the tumors (e.g. BRCA mutant vs non-BRCA mutant) influences those interactions. These analyses will include an assessment of how the tumors engage with the gut microbiome and vice versa.
Roger Greenberg, MD, PhD
The goal of this research is to identify and target mechanisms of resistance to PARP inhibitors (PARPi) and Platinum based chemotherapies in BRCA1 and BRCA2 mutant cancers. This work has led to the initiation of clinical trials using approaches to identify patients that are more likely to respond to PARPi therapy. Dr. Greenberg’s lab has made substantial progress stemming from their discoveries as part of their earlier team science grant. The team defined alternative pathways to BRCA-Rad51 recombination that are required for survival in BRCA mutant cells. They have also identified the entire network of these alternative DNA repair mechanisms, providing a rich source of factors to investigate in BRCA mutant cells that have become resistant to PARPi. Another aspect of the research comes from discovery of a new gene that is required for survival of BRCA mutant cells and dramatically increases their sensitivity to PARPi. This work is a promising avenue to begin drug discovery efforts.
Katherine L. Nathanson, MD
The funding from the Basser Center for BRCA supports two on-going projects. In the first project, Dr. Nathanson’s team is expanding on their prior finding that a sub-set of BRCA1/2 mutation-associated cancers do not display loss of heterozygosity (LOH). Dr. Nathanson is evaluating whether molecular and pathological features vary between tumors associated with different mutational types (missense, large genomic rearrangements vs. frameshift/truncating) and locations (exon 11 vs. non-exon 11). The team is also evaluating immunogenicity in BRCA1/2 mutation-associated breast and ovarian tumors. They have demonstrated that levels of homologous recombination deficiency are inversely associated with immunogenicity in primary BRCA1/2 breast cancers, a phenotype further modulated by hormone receptor expression. As efforts in the clinic continue to advance combinations of immune checkpoint blockade, PARP1 inhibitors, and platinum chemotherapy for patients with BRCA1/2 mutation-associated cancers, the team’s findings may help direct optimal trial design and interpretation. For BRCA1/2 ovarian cancers, Dr. Nathanson found that a subset of BRCA1/2-deficient ovarian cancers exhibit an immune suppressed phenotype linked to PTEN deficiency or BRCA1 promoter hypermethylation, indicating that these tumor intrinsic features may be more important than mutational or neoantigen load in determining immunogenicity and potential response to immune checkpoint blockade in BRCA1/2-deficient ovarian cancers.
Quantitative Proteomics to Identify Mediators of Therapy Response in BRCA-Cancer
Principal Investigator Sharon B. Cantor, PhD, of University of Massachusetts, is funded to define the protein landscape of therapy, sensitive vs. resistant hereditary breast cancer to predict therapy response. and define targets to disrupt resistance mechanisms. The goal of the study is to comprehensively reveal how genetic loss of the BRCA- pathway alters the proteome by utilizing quantitative mass-spectrometry-based proteomics to first gain an unbiased examination of protein machinery in BRCA mutant and proficient cancer cells. Second, by comparing cisplatin sensitive vs. resistant BRCA cancer cells, to unmask proteomic changes that favor chemoresistance. Collectively, the grant aims to provide critical new selective targets that could be used in conjunction with current therapies to prevent chemoresistance.
Defining the Molecular Mechanisms Underlying BRCA2 and RAD51 PARP Lesion Processing
Ryan B. Jensen, PhD, of Yale University is funded to lead a study exploring resistance to PARP inhibitors, namely the need to elucidate how PARP inhibitors (PARPi) cause cell death in BRCA mutant but not normal cells. The study will also seek to define how individual PARPi may act through distinct mechanisms, either by “trapping” PARP-DNA complexes or by inhibiting repair of (single-stranded DNA (ssDNA) nicks that are subsequently converted to double-stranded breaks (DSBs). The study will interrogate the explicit biochemical function(s) compromised by pathogenic BRCA2 mutations. Sensitivity to various PARPi will be assessed with strong, intermediate, or weak trapping activity (e.g. talazoparib, olaparib, and veliparib, respectively), and the function(s) reconstituted by “reversion” mutations identified in patients with PARPi-resistant tumors will be investigated with the goal of identifying functional attributes necessary for PARPi sensitivity.
Identifying Drivers of BRCA2 Mutation Associated Predisposition to Cancer
For this study, Principal Investigator Shailja Pathania, PhD, University of Massachusetts, is funded to examine the molecular origins of BRCA2 mutant cancer, particularly the identification of genetic changes that drive normal heterozygous cells in BRCA2 mutation carriers (BRCA2mut/+) to become tumor cells. Preliminary data that shows that (BRCA2mut/+) breast cells are sensitive to replication stress (RS) inducing DNA damage. The study hypothesizes that the tumors that eventually arise from BRCA2mut/+ cells must tolerate the RS inherent to oncogenic transformation. This tolerance might be dependent on acquisition of additional modifications like loss of p53 and/or other genes and/or pathways. To identify additional genes and pathways that allow BRCA2mut/+ cells to survive RS, a genome-scale screening approach will be utilized, and then human tumors can be queried for mutations or altered expression of the genes discovered in the screen. Identification of such genetic changes will provide insight into the first step/s that occur in the path to tumor formation in cells of BRCA2 mutation carriers.
Modeling Early Detection and Prevention of BRCA1-Related Breast Cancer
Principal Investigator Hui Zong, PhD, of University of Virginia is funded to explore the development of breast cancer in women with BRCA1 mutations. A significant gap in knowledge regarding the progressive kinetics of pre-malignant mutant cells makes it virtually impossible to precisely determine when to intervene, which is a particular challenge for women who want to maintain their fertility. This study seeks to tackle this problem using a mouse model called MADM (mosaic analysis with double markers), which is ideal for studying tumor initiation because the model mimics the clonal origin of cancer in human patients and the direct comparison between mutant and wildtype cells allows the detection of even the subtlest anomalies at early stages. The model will have two specific aims: to take advantage of the single-cell resolution provided by MADM to thoroughly characterize tumor initiation stage, focusing on early progression kinetics, varied susceptibility of different cell types, and spatial heterogeneity of progression in the mammary gland; and to quantitatively evaluate whether the synthetic lethality of PARP-1 inhibitor in BRCA1-mutant cells could exert tumor-prevention activity.
Previous Grant Awardees
Vaccination to Prevent BRCA1/2-Related Cancer
In this Breakthrough Science Team Award, principal investigators Robert Vonderheide, MD, DPhil and David Weiner, PhD and co-investigators Daniel Powell, PhD, Andrea Facciabene, MD, PhD, Katherine Nathanson, MD, E. John Wherry, PhD, and Ben Stanger, MD, PhD were funded for three years to study the development of a novel vaccine that prevents BRCA1/2-related cancer in healthy individuals who carry BRCA1/2 mutations. As a first step toward this overall goal, this study worked to determine the clinical and immunological impact of vaccinating high-risk patients in remission after adjuvant therapy using TERT DNA with or without IL-12 DNA; optimize the generation of anti-tumor immunity in genetic mouse models of BRCA1/2-related cancers using prophylactic DNA-based vaccines; and discover new T cell antigens based tumor mutations in BRCA1/2 cancers.
Molecular Determinants of Chemo-Responsiveness of BRCA Mutant Cancers
For this three-year Breakthrough Science Team Award, principal investigators Roger Greenberg, MD, PhD, Lin Zhang,MD, Andy Minn, MD, PhD, and Warren Pear, MD, PhD collaborated with basic and clinical investigators from four core laboratories, including Wei Tong, PhD, Robert Mach, PhD, David Mankoff, MD, PhD, and Angela DeMichele, MD, MSCE to study the molecular basis of cell intrinsic and extrinsic mechanisms that dictate chemo-responsiveness of BRCA mutant cancers, and identify novel strategies that overcome common mechanisms of resistance.
Targeting the ATR/CHK1 Pathway in Treatment
Principal investigators Eric Brown, PhD and Fiona Simpkins, MD and co-investigators Rugang Zhang, PhD and Mark Morgan, MD were funded for two years for this Breakthrough Science Team Award to determine if ovarian and pancreatic BRCA2-deficient cancers can be treated by targeting the ATR/CHK1 pathway as a primary line of therapy, or be used secondarily following the development of PARPi resistance. This study may lead to the development of new therapeutic strategies for patients with BRCA1/2-deficient cancers and could spur future Phase I/II trials evaluating ATR/CHK1 inhibition as an alternative primary treatment or secondary treatment for BRCA1/2-mutation carriers.
Optimizing Access to Genetic Services for BRCA1/2 Mutation Carriers
In this Outreach and Implementation Science Award, principal investigator Angela Bradbury, MD was funded for three years to test the effectiveness of TeleGenetics (telephone or videoconferencing) to provide cancer risk counseling and cancer genetic testing to individuals in communities with limited access to genetic services. Patients were randomly selected to receive remote genetic services at their community provider’s site by telephone or videoconferencing with a Penn genetic counselor or a usual care arm, where they received information on resources for genetic services in their area. The project aims to expand access to expert genetic providers in geographically and socio-demographically diverse populations with limited access to genetic services, improving the delivery of information and expanding the population of people who can benefit from learning about BRCA1/2-associated cancer risk.
Roles of BRCA1 in RAD51-Mediated Homologous Recombination and Tumor Suppression
Principal investigator Patrick Sung, DPhil of Yale University was funded for one year to explore deeper molecular understandings of the genes BRCA1 and BARD1 and their role in homologous recombination (a natural process cells use to accurately repair harmful breaks in strands of DNA) to better develop strategies for the treatment of cancer stemming from BRCA mutations. To overcome the difficulties of working with BRCA in vitro, the team has developed a system to obtain soluble, monodispersed BRCA1 (in combination with BARD1) in large quantities for this two part study, which includes: the generation and testing of BRCA1 mutations in various cell-based assays to assess biological significance of protein-ligand interactions; and deciphering how BRCA1-BARD1 impacts different stages of homologous recombination.
Determine the Role of Dormant Origin Firing in Modulating BRCA1 Haploinsufficiency
For this one year study, principal investigator Tony T. Huang, Ph.D. from New York University School of Medicine was funded to determine causes of haploinsufficiency, a condition that arises where the function of a gene is reduced resulting in abnormalities. The study focused on BRCA1 mutations and looked to prevent instability in the chromosomes as cells are replicating. The study looked at a recent discovery of a protein implicated in a type of anemia known as Fanconi anemia that may have a positive impact. The study also mapped locations where the gene doesn’t replicate properly using an innovative deep sequencing technique that compares normal human mammary (breast) epithelial cells with BRCA1 mutations carriers.
Analysis of BRCA1 Missense Variants in DNA Repair
This basic science project, headed by Jeffrey D. Parvin, M.D., Ph.D. of Ohio State University, was funded for one year and focused on the impact of missense alterations on the BRCA1 protein function in DNA repair. In collaboration with the University of Washington, a novel approach was used to analyze thousands of genetic variations in BRCA1. The study was intended to have an immediately translatable clinical use, as the results from the functional assay can be combined with information in order to advise women with a BRCA1 variant of unknown significance on their likely breast cancer predisposition. Additionally, there is a basic science impact in terms of understanding the structure-function relationships of BRCA1 at very high resolution.
Targeting DNA Polymerase θ for Precision Medicine in BRCA Deficient Cancers
In a collaboration between Temple and Stanford Universities, this study, led by principal investigator Richard T. Pomerantz, Ph.D., was funded for one year and explored the use of targeting DNA polymerase theta (Polθ), which is highly upregulated in breast and ovarian cancers and corresponds to a poor clinical outcome for breast cancer patients. Recent groundbreaking studies have demonstrated a synthetic lethal relationship between Polθ and the BRCA pathway of homologous recombination, and strongly indicates that inhibition of Polθ will selectively kill BRCA deficient cancer cells. Because BRCA deficient cells often become resistant to Poly (ADP-ribose) polymerase (PARP) inhibitors the development of promising new DNA repair drug targets, such as Polθ, is important for identifying personalized non-toxic treatments for patients with BRCA deficient cells.
Mechanism Based Strategies to Overcome Resistance and Augment Response to Targeted Therapy in BRCA Mutant Cancer
In this Basser Team Science Award, principal Investigator Junjie Chen, PhD (MD Anderson Cancer Center) led a multi-institutional team funded for two years to study novel mechanisms of chemotherapy responsiveness in BRCA mutation-related cancers and overcoming therapy resistance arising from these mechanisms. These studies were performed at the level of basic laboratory investigation, using clinical samples from BRCA mutant breast and ovarian cancers that are naïve to therapy and in those that have acquired resistance. Achieving these objectives allowed for the development of more efficacious treatment strategies for BRCA patients.
Using PARP Inhibitors in the Treatment of Cancer
PARP inhibitors are a promising class of cancer treatment drugs. However, some cancers are resistant to PARP inhibitors while others can become resistant to PARP inhibitors over time. CDK12 is a protein that appears to help the cancer cell resist the beneficial effects of PARP inhibitors. So, stopping CDK12 might stop the cell’s ability to resist treatment. One way to stop CDK12 could be to promote THZ-5-31-1, which is a protein that inhibits CDK12. For this Basser Innovation Award, principal investigator Geoffrey Shapiro, MD, PhD (Dana-Farber Cancer Institute) was funded for one year to assess how promoting THZ-5-31-1 might stop the body from accidentally repairing breast cancer cells. Also, he explored if pairing THZ-5-31-1 with a PARP inhibitor could stop a tumor from growing.
Predicting the Best Treatment for Each Patient
Knowing the protein make-up of a tumor can help doctors predict how an individual patient will respond to different types of cancer treatments. For this Basser Innovation Award, principal investigator Zoltan Szallasi, MD (Boston Children’s Hospital) was funded for one year to establish a profile of the 53BP1 and Ku70 proteins that will help doctors predict how individual people with BRCA-associated cancers would respond to PARP inhibitors and platinum-based therapy. This defined a mutational profile measuring the relative activity of 53BP1 and Ku70 in BRCA mutant tumors, which will be an important step towards establishing a robust biomarker that reliably predicts response to platinum or PARP inhibitor based therapy in BRCA mutation carriers.
Inhibiting SIRT2 Activity to Inhibit BRCA Activity
BRCA proteins, which are made from BRCA genes, typically help in the repair of DNA damage that occurs in a cell’s life. There are other proteins, like SIRT2, that regulate how BRCA proteins perform this role in the cell. For this Basser Innovation Award, principal Investigator David Yu, MD, PhD (Emory University) was funded for one year to determine the significance of SIRT2’s regulation over BRCA1 protein activity and to determine if inhibiting SIRT2 might kill cells and tumors with BRCA1/BRCA2 dysregulation.
Development of a Culturally-tailored Decision Aid on BRCA Genetic Testing for Orthodox Jews
While it is known that 1 in 40 people of Ashkenazi Jewish descent carry a BRCA1 or BRCA2 gene mutation, the Orthodox Jewish community remains an under-studied population. Principal investigator Katherine Crew, MD (Columbia University) was funded for one year to develop a web-based decision aid, RealRisks, which is designed to improve genetic testing knowledge and accuracy of breast cancer risk perceptions, as well as self-efficacy to engage in a collaborative dialogue about BRCA genetic testing. The goal of this work was to develop a culturally-tailored decision aid for Orthodox Jewish women to enhance informed decision-making regarding BRCA genetic testing.
Targeting Familial Breast Cancer with RAD52 Inhibitors
In this Basser Innovation Award, principal investigator Alexander Mazin, PhD (Drexel University) was funded to analyze the effect of RAD52 inhibitors in BRCA1/2 cells alone and in combination with therapeutic drugs, analyze the mechanism of RAD52 inhibition in vitro, and develop more effective analogs of RAD52 inhibitors through a medicinal chemistry approach.
Analyses of the Genetic Interaction Between PARP2 and the BRCA1/BRCA2 Tumor Suppressors: Towards Selective PARP Inhibitors
For this Basser Innovation Award, principal investigator Sonia Franco, MD, PhD (Johns Hopkins University) was funded to employ a genetic approach to test the hypothesis that PARP2 has PARP1-independent functions in the suppression of genomic instability in BRCA-deficient backgrounds. This will help define the mechanisms of action for PARPi in BRCA cells, setting the stage for future development of biomarkers and more specific PARP inhibitors.
The Role of BRCA1 Isoforms in PARP Inhibitor and Platinum Resistance
Principal investigator Neil Johnson, PhD (Fox Chase Cancer Center) was funded for this Basser Innovation Award to identify and characterize BRCA1 isoforms that are capable of contributing to DNA repair and drug resistance. This characterization could be useful for predicting which patients will have lasting responses to PARP inhibitor or platinum therapy based on establishing relationships between specific BRCA1 mutations and the likelihood of expressing particular BRCA1 isoforms.
When Numbers Matter: Decision Support for BRCA Genetic Testing
Principal Investigator Katherine Crew, MD (Columbia University) was funded to develop a program to screen underserved communities for BRCA mutations in the New York City area.
Minimizing Adverse Outcomes Following RRSO in BRCA1/2 Mutation Carriers
In this Cancer Risk Reduction and Prevention Award, Susan Domchek, MD was funded to comprehensively investigate the effect of risk-reducing oophorectomy (RRSO) on a variety of health outcomes. Findings from this study will be helpful in advising patients on the best timing for oophorectomy and in establishing whether interventions to treat side effects are needed. To date, Dr. Domchek's team developed an interdisciplinary and international project to prospectively study BRCA carriers undergoing RRSO and have recruited 231 women into an extensive survey study of RRSO effects for women who have already undergone the procedure. In this grant cycle, Dr. Domchek's team began prospective recruitment and increased the survey study response rate to 500.
Comprehensive Evaluation of Cancer Risk Modifiers in BRCA1/2 Mutation Carriers
Timothy Rebbeck, PhD was awarded funding to study factors that modify BRCA1/2 cancer risks in carriers to provide information that may aid women and their providers in making optimal decisions about cancer prevention strategies in this Cancer Risk Reduction and Prevention Award. Dr. Rebbeck will further focus these studies on under-represented groups. To date, Dr. Rebbeck's team has undertaken a comprehensive synopsis of factors that modify BRCA1/2-associated cancer risks such as reproductive history, exposures, and modifying genes. In this grant cycle, Dr. Rebbeck's team will extend the above analyses and focus on the recruitment and analyses of these parameters in underrepresented populations.
Development of Vaccine Targeting the Tumor Vasculature for the Prevention of BRCA-Deficient Tumors
In this Cancer Risk Reduction and Prevention Award, Andrea Facciabene, PhD worked to develop a potential vaccine for BRCA-related cancers that may teach the immune system to react to and destroy cancerous tissue. To date, Dr. Facciabene's lab identified the device needed to deliver the vaccine to humans, developed new DNA vectors for the vaccine to perform studies necessary to submit to FDA for trials in humans, and completed all pre-IND (investigational new drug) documentation necessary to submit to FDA. Dr. Facciabene's lab performed safety studies in an animal model in preparation for submitting an IND to FDA for clinical trials in humans.
Predictors of Healthy Mood and Memory After Oophorectomy
C. Neill Epperson, MD was funded to study mood and memory in BRCA carriers before and after oophorectomy to determine who is at risk for adverse responses to the surgery and to determine ways to target prevention and treatment for mood and memory problems post-oophorectomy. For this Cancer Risk Reduction and Prevention Award, Dr. Epperson performed two randomized clinical trials to test hormone replacement therapy and a psychostimulant medication in women who were undergoing risk-reducing oophorectomy and women who had already undergone oophorectomy.
A Zebrafish Mutagenesis Screen to Identify Genes, Promote Initiation and Progression of BRCA2 Associated Ovarian Cancer
For this Cancer Risk Reduction and Prevention Award, Michael Pack, MD was funded to identify and study mutations that occur in the development of BRCA2-related ovarian cancers in a zebrafish model. In addition to providing insight into BRCA2's role in the development of ovarian cancer, the mutations identified in the development of ovarian cancer may help define risk factors for the development of ovarian cancer in carriers, identify novel targets for anti-cancer drugs, and alter our approach to detection and treatment of BRCA2-related ovarian cancer.
A Fully Optimized CAR RNA T Cell-based Therapy for BRCA Cancer Treatment
Daniel Powell, PhD was funded to further develop a potent immune-based therapy for BRCA-related breast cancers that teaches the immune system's T-cells to attack the cancer for this Cancer Risk Reduction and Prevention Award. Dr. Powell's laboratory focused on developing this potential therapy for trial in the clinic by exploring possible allergic responses and by developing a vector for delivering the therapy to humans in a future pilot study.
Eating and Exercise for BRCA+ Survivors: Addressing Heart and Bone Health
Kathryn Schmitz, PhD was funded to study the efficacy of a commercially available web-based nutrition and exercise program on a novel population of breast cancer survivors who have undergone risk-reducing oophorectomy under age 45 and who have not been on hormone replacement therapy for at least two years. For this Cancer Risk Reduction and Prevention Award, Dr. Schmitz studied cardiovascular and bone outcomes in order to provide a balanced understanding of the potential benefits of nutrition and exercise on these outcomes.
The Stone Family Award in BRCA Prevention Research: Telomerase Vaccination to Prevent BRCA1/2 Related Cancer
David Weiner, PhD and Robert Vonderheide, MD, DPhil, were funded to study a prevention vaccine aimed at reducing the risk of cancer is BRCA mutation carriers for this Cancer Risk Reduction and Prevention Award. Using an enzyme called hTERT, Drs. Weiner and Vonderheide aimed to develop a vaccine that teaches the body's immune system to fight BRCA-related cancers. They performed a series of preclinical studies using several mouse models of immune-prevention that were designed to prove the immunological concept, optimize the vaccine, and provide necessary data to file an investigational new drug application with FDA, the first step towards studying the vaccine in humans. Drs. Weiner and Vonderheide's work has been made possible by the Stone Family Award, created by Norman L. Stone, W'52 and Carol Stone to advance prevention research on BRCA1/2.
Chromatin Modifying Factors and BRCA1/2
For this Cancer Therapy Targets and Predictors of Therapy Response Award, Roger Greenberg, MD, PhD was funded to study other DNA errors present in BRCA-related cancers to determine if these errors predict response to certain therapies, towards the end of developing better chemotherapy approaches based on the specific genetic changes in BRCA-related cancers. To date, Dr. Greenberg's lab has identified molecular mechanisms that influence DNA damage responses to clinically important therapies and discovered a new BRCA1-related syndrome. In this grant cycle, Dr. Greenberg's lab will work to identify additional molecular mechanisms by which BRCA1 functions that may offer new targets for enhancing sensitivity to chemotherapies in BRCA-related cancers.
Interferon-Related DNA Damage Resistance Signature (IRDS) in BRCA Mutant Tumor
Andrew Minn, MD, PhD was funded for this Cancer Therapy Targets and Predictors of Therapy Response Award to study how cells that surround cancers can play an important role in shaping cancer behavior. Dr. Minn's project aims to identify and understand signals that are sent from non-cancer cells to cancer cells that contribute to therapy resistance. To date, Dr. Minn's lab has uncovered how pathways that normally respond to viral infection can control treatment resistance, particularly in BRCA1-related breast cancers, and how inhibiting these pathways can improve the effectiveness of therapies. In this grant cycle, Dr. Minn will study these pathways and test a hypothesis that a step of this pathway is a potential drug target for addressing therapy resistance.
The Role of BRCA1 and Genomic Instability in Pancreatic Cancer Metastasis
Ben Stanger, MD, PhD was funded for this Cancer Therapy Targets and Predictors of Therapy Response Award to study the role of BRCA2 in the development of pancreatic cancers, specifically the role of BRCA2 in metastatic disease. Dr. Stanger's team will use mice models to study the role of BRCA2 in pancreatic cancer and to determine whether BRCA2 mutations and mutations in a related gene called PALB2 increase sensitivity to inhibitors of other molecular pathways.
Functional Genetic Approached to Identify MicroRNAs Regulating BRCAness in Breast and Ovarian Cancer
For this Cancer Therapy Targets and Predictors of Therapy Response Award, Lin Zhang, MD was funded to study the role of microRNA's, which are molecules that affect the action of genes, in the development of cancer and the sensitivity of cancers to chemotherapies. Dr. Zhang's team aims to identify the microRNAs present that make cancers exhibit features of BRCA-related cancers ("BRCAness"), to predict sensitivity to chemotherapies including PARP inhibitors and to develop well-annotated databases of breast and ovarian cancers for BRCA researchers.
Effects of AURKA and BRCA1 Dysregulation on Replication Fork Stability and Cell Survival Upon ATR/CHK1 Inhibition
Eric Brown, PhD was funded for this Cancer Therapy Targets and Predictors of Therapy Response Award to study pathways involved in the development and drug-susceptibility of cancers that are related to BRCA1. AURKA and ATR/CHK1 are both pathways that are highly relevant in breast cancers. By studying the role of different pathways, Dr. Brown's team aims to translate their findings into potential uses of pathway-inhibitors in breast cancers that are BRCA1-deficient.
Whole Genome Sequencing of Breast and Ovarian Cancers Associated with BRCA1/2 Mutations
Kate Nathanson, MD, was funded for this Cancer Therapy Targets and Predictors of Therapy Response Award to sequence the DNA of breast and ovarian tumors for BRCA1/2 carriers to understand the molecular changes that may represent new targets for treatment or predict drug sensitivity or resistance to current regimens. To date, Dr. Nathanson's lab has identified multiple changes in 48 known cancer genes that are likely driving the growth of BRCA-related tumors and changes which suggest sensitivity to a range of experimental drugs. In the next cycle, Dr. Nathanson's lab will expand their analysis to explore thousands of gene mutations in BRCA-related tumors in the hopes of identifying novel pathways and drug targets in BRCA1 and BRCA2 mutated tumors.
Blood-borne Biomarkers of Dysplasia and Early Cancer in Patients with BRCA Mutations
Dr. Andrew Rhim's laboratory recently found that cells from the pancreas (and other organs) can enter the bloodstream when a pre-cancerous lesion is present but long before a tumor has formed. For this Early Detection Award, Dr. Rhim's work focused on applying this discovery of circulating epithelial cells (CEC's) to develop a screening method for detecting BRCA-related cancers early. To date, Dr. Rhim has initiated serial blood sampling in BRCA carriers treated at the Basser Center and has detected CEC's in BRCA mutation carriers without clinical diagnoses of cancer. In this grant cycle, Dr. Rhim continued to follow BRCA carriers with serial blood sampling to determine if CEC's can be used to identify patients with early cancer. In addition, Dr. Rhim's team profiled the genetic make-up of these cells to gain more information about their potential to develop into cancer.
Imaging Biomarkets for Risk Reduction Management of BRCA1/2 Carriers
In this Early Detection Award, Despina Kontos, PhD was funded to study whether dynamic contrast-enhanced MRI (DCE-MRI) provides useful information about the actual effect of risk-reducing methods on breast cancer risk. If DCE-MRI helps to predict which women are benefiting from each risk-reducing intervention, Kontos' team will provide new clinical decision-aid tools for improving risk-reduction and quality of life for BRCA carriers.
Next Generation Tomosynthesis Imaging for BRCA1/2 Carriers
Andrew Maidment, PhD, FAAPM was funded for this Early Detection Award to study digital breast tomosynthesis (DBT), a novel imaging modality that may replace mammography in the future. DBT is currently limited to the detection of non-calcified lesions which is problematic because many cancers detected in BRCA2 carriers have cancers that present as calcified lesions. Dr. Maidment's team aimed to develop the next generation of DBT systems that may benefit BRCA mutation carriers by increasing early detection of BRCA-related breast cancers.
REACH: Research to Evaluate Adolescents and Early Communication of Hereditary Risk
In this Communication and Risk Assessment Award, Dr. Angela Bradbury was awarded funding to study communication about hereditary cancer risk within families, with a focus on adolescents. Her work aimed to inform interventions that increase preventative behaviors and minimize adverse psychological outcomes in adolescents and young adults from BRCA families. To date, Dr. Bradbury's team reached 141 interviews with parents reporting on communication with 287 children, and also enrolled girls aged 11-19 years for interviews on knowledge and beliefs about breast cancer risk. During this grant cycle, Dr. Bradbury's team aimed to complete recruitment, analyze the relationship between what parents tell their children and the psychosocial adjustment of children, and begin to develop psychosocial interventions.
AFFIRM: Assessment of Fertility and Factors Influencing Reproduction and Menopause in BRCA Mutation Carriers
Clarisa Gracia, MD, MSCE was funded for this Communication and Risk Assessment Award to study the impact of carrying a BRCA mutation on fertility and reproductive decisions. BRCA mutation carriers and a control group of BRCA1/2 negative women will be recruited to provide a blood spot for hormone level testing and to complete a questionnaire on fertility and the impact of BRCA on reproductive decision-making.
Chromatin Modifying Factors and BRCA1/2
Roger Greenberg, MD, PhD was funded for this Cancer Therapy Targets and Predictors of Therapy Response Award to study other DNA errors present in BRCA-related cancers to determine if these errors predict response to certain therapies, towards the end of developing better chemotherapy approaches based on the specific genetic changes in BRCA-related cancers.
Interferon-Related DNA Damage Resistance Signature (IRDS) in BRCA Mutant Tumor
For this Cancer Therapy Targets and Predictors of Therapy Response Award, Andrew Minn, MD, PhD had been funded to study changes in the DNA of BRCA-related tumors to evaluate whether these DNA changes predict response to chemo- and radiation therapies in order to determine optimal treatment strategies.
Whole Genome Sequencing of Breast and Ovarian Cancers Associated with BRCA1/2 Mutations
For this Cancer Therapy Targets and Predictors of Therapy Response Award, Kate Nathanson, MD, was funded to sequence the DNA of breast and ovarian tumors for BRCA1/2 carriers to understand the molecular changes that may represent new targets for treatment or predict drug sensitivity or resistance to current regimens.
Development of Molecular Imaging of Tumor Vasculature for the Early Detection of Hereditary Ovarian and Breast Cancer
For this Early Detection Award, Drs. George Coukos and Chungsheng Li investigated innovative molecular imaging techniques that visualize the tiny veins that grow to feed cancers which could lead to better methods for early detection of BRCA-related cancers.